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Background: There is a paucity of research evaluating parental proxy decision making 
for pediatric clinical trial participation. Fragile X Syndrome (FXS) is a rare genetic 
condition involving intellectual disability as its main symptom. Clinical trials have been 
offered and are under development. As intellectual disability directly affects an 
individual’s personality, perceptions about trial participation and the potential for a 
disease-modifying therapy is likely different from the perceptions of parents raising a 
child with a physical disability or illness.  
Objective: To improve understanding of parental proxy decision making for clinical trial 
participation of children with intellectual disability. 
Methods: Interviews were conducted with parents from two groups: those who chose to 
1) enroll their child with FXS in a trial; and 2) decline trial participation for their child 
with FXS. Parents were recruited through support groups. Interviews were transcribed 
and coded using thematic analysis. 
Results: The most prevalent contextual decisional factor was attitudes about FXS 
medications. The most frequent trial-specific decisional factors were parental perceptions 
of the mechanism of the experimental drug, barriers and risks, and the match between 
parentally perceived purpose of the trial and their child’s specific symptomatology. 
Parents’ decision making processes involved weighing the risks and benefits of 
participation. Many parents reported making trial decisions primarily alone or with the 
support of their partner. All parents reported low decisional regret, though decisional 
conflict was found to range from low to high. 
 iii 
Conclusions: The most prevalent, primary decisional factors synthesized by parents 
within their decision-making process were their strongly negative or positive attitudes 
towards medicating their child’s FXS symptoms, excessive travel to trial site and high 
number of required appointments, and perceived risk of physical side effects. Potential 
for direct individual benefit from participation most directly shaped parents’ trial 
expectations and hopes, providing ultimate motivation for participation and resulting in 
high therapeutic optimism amongst parents who elected trial participation. Our results 
offer insight into potential targets of downstream research evaluating interventions to 
facilitate these decisions and reduce undesirable decisional outcomes. 
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There is a paucity of research evaluating parental decision making for pediatric 
clinical trial participation. These are high stakes decisions that may impact parent and 
child well-being (physical and psychosocial), as well as the effectiveness of the drug 
development process that is integral to the improvement of medical care. Due to the 
inherent lack of data supporting a novel experimental drugs’ efficacy or safety, decisions 
to participate in clinical trials should be preference-based rather than prescribed or 
recommended by the health care community. Because there are concerns that parental 
decisions may not always be fully deliberated (Chang, 2008; Snethen et al., 2006), 
investigation of parental decision-making can help to inform efforts to improve this 
process. This study aimed to improve understanding of parental decision making for 
clinical trial participation of children with intellectual disability. Specifically, it focused 
on parent experiences of clinical trials for Fragile X Syndrome using semi-structured 
interviews. 
 Fragile X Syndrome (FXS) is an inherited genetic condition involving changes to 
the FMR1 gene located on the X chromosome. Such changes are estimated to occur as 
often as 1 in 2500 individuals (Hagerman, 2008). Its symptoms include cognitive 
impairment (ranging from mild learning disability to significant intellectual disability) 
behavior problems (such as inattention and hyperactivity), and less frequently, autism 
spectrum disorders (Bailey et al., 2008). Overall, FXS is the most common inherited 
cause of intellectual disability and the most common single-gene cause of autism 









 Clinical trials are essential for drug development. There are four stages of studies 
of therapeutic clinical trials. First, phase 1 trials include healthy volunteers, or especially 
in the case of rare disorders, people with the disease or condition in question. Phase 1 
trials aim to elucidate drug safety, side effects, and appropriate dosage. Approximately 
70% of drugs complete phase 1 study to enter phase 2, which provides data on efficacy 
and side effects of the drug in development. About 33% of drugs in phase 2 will move to 
phase 3, in which expanded studies enable further research into the efficacy and 
monitoring of adverse reactions. After moving through the stages of clinical trials the 
FDA examines data from clinical and preclinical studies to either approve or not approve 
the drug’s marketing. Approximately 25-30% of novel drugs in phase 3 clinical trials are 
approved for marketing and move to phase four, in which the FDA follows the drug and 
monitors its post-market safety and efficacy (FDA, 2015).  
 In some cases, the process described above is modified for trials for rare 
disorders. Clinical trials have particular importance in the rare disease community, where 
advances in drug development have lagged behind more common diseases, target 
populations are significantly smaller, and funding is often more difficult to ascertain.  
Decisions about Participation in Clinical Trials: Pediatrics 
 
 Most research on decision making for clinical trials examines adults making 




Wenzel et al., 2015). In pediatrics, the majority of data on parental clinical trial decision-
making comes from the pediatric oncology context. An analysis of 22 qualitative studies 
of decision making for pediatric oncology trials deemed it difficult to achieve informed 
consent due to complex research protocols, as well as parents’ emotional distress and 
dependence on the consenting physician. Parents have frequently and inaccurately 
attributed therapeutic intent to research participation. They desire to act in the best 
interest of their child, and in this context have reported fearing they made the ‘wrong 
decision’ about trial participation (deVries et al., 2011).   
A literature review of parental decision making about care and treatment 
(including, but not limited to clinical trial participation) for children with cancer reveals 
that child’s quality of life/wellbeing, parental hope/expectations, support/supportive care, 
communication, and information were important themes in considering these decisions 
(Markward et al., 2013). 
 A recent qualitative study evaluated parent and clinician motivations and 
expectations for involvement in clinical trials for the rare pediatric disorder Duchenne 
muscular dystrophy (Peay et al., 2014). High trial expectations of direct benefit were 
reported by parents and many clinicians, however many parents were able to differentiate 
expectations from hope for a cure. Parental expectations manifest from the views of other 
parents, advocacy organizations, and trial sponsors. Parents’ primary motivation for 
enrolling was the potential for benefit, and the decision was described as easy or a ‘non-
decision.’ They did not perceive clinicians to have a significant role in their decision-
making. It is unknown whether these findings represent experiences of other parents 




 Therapeutic misconception, or the belief that the purpose of a clinical trial is to 
benefit the individual patient rather than gather data to develop scientific knowledge, is a 
particular bioethical concern for decision-making in clinical trials. Therapeutic 
misconception has been identified as a potential issue within pediatric as well as adult 
contexts (Peay et al., 2014; Jansen et al., 2011). Some researchers have emphasized the 
idea that therapeutic misconception may be a mislabeling. This argument posits that what 
is labeled as therapeutic misconception may actually be a situation in which a parent is 
hoping that his/her child will receive a treatment that is later shown to be better than the 
standard treatment, and that this is the purpose of clinical trials (Shilling & Young, 2009). 
Nevertheless, unrealistic situational optimism surrounding clinical trials raises concern as 
a potential threat to informed decision-making and source of exploitation of research 
participants (Jansen et al., 2011).   
 A study evaluating perceived benefits and barriers to pediatric clinical trials 
suggests potential benefit of drug, perceived harm due to mistrust of researchers, and 
logistics to be primary factors in decision-making about clinical trials in pediatrics 
(Barakat et al., 2013). Another survey of 261 parents of healthy children, and parents of 
children ill with conditions including diabetes, asthma, cystic fibrosis, phenylketonuria, 
and gastroesophageal reflux disease, myopathy, and encephalopathy, identified “direct 
benefits for their child” as the main factor motivating participation in pediatric clinical 
research (Vanhelst, 2013).  
Specific for clinical trials in FXS, the degree to which adult affected individuals 
are believed to be able to consent for trials has been investigated. A recent study 




all capable of participating in the decision to participate in the trial, yet a majority of 
affected individuals were perceived to be able to participate at some level in the consent 
or assent process (Bailey et al., 2014).  
No study has yet examined parental decision-making for enrollment of children 
with intellectual disability in a clinical trial of drug development. It is not clear how 
parental clinical trial decision-making may be different in the context of a primarily 
cognitive condition rather than a primarily physical condition. Having a richer 
understanding of this decision within this context could help inform future quantitative 
studies that aim to examine ways of improving facilitation of these decisions for parents. 
Parenting a Child with Intellectual or Developmental Disability 
 
 Most pediatric clinical trial research has been conducted on drugs for diseases 
with primarily physical symptoms (such as cancer and Duchenne muscular dystrophy). In 
considering trials for FXS, it is first important to contextualize this research in what is 
known about raising a child afflicted by a condition with primarily cognitive symptoms. 
Because intellectual disability is relatively common, with between 1 in 50 and 1 in 20 
families with affected children worldwide, there is data describing the experience of 
raising a child with intellectual disability or developmental delay. In the vast majority of 
cases, parents and other family members care for children with intellectual disabilities 
directly (Families Special Interest Research Group of IASSIDD, 2014).  
Parental Psychological Wellbeing 
 
 While mothers of children with intellectual disabilities report greater parenting 
demands, increased stress levels, and poorer physical and psychological health than 




of children with intellectual disability (ID) report normative levels of well-being (Olsson 
& Hwang 2001; Saloviita et al., 2003; Blacher et al., 2005; Singer 2006; Gerstein et al., 
2009; Miodrag & Hodapp 2010; Glidden & Schoolcraft 2003; Baker et al., 2005; Glidden 
& Jobe 2006; Olsson et al., 2008). There is less known about fathers’ well-being; 
however, some research suggests that the association between parenting a child with ID 
and lower well-being is even less pronounced among fathers than mothers, who generally 
report psychological well-being. Fathers similarly report lower levels of psychological 
distress than mothers (Olsson & Hwang 2001; Salvoiita et al., 2003; Gerstein et al. 2009; 
Emerson et al. 2010; MacDonald & Hastings 2010). 
Factors Associated with Variation in Parental Psychological Wellbeing 
 
 Parental well-being appears to be highly dependent upon the affected child’s 
degree of maladaptive behavior. Child behavior problems, rather than ID per se, can be 
associated with lower levels of parental wellbeing (Glidden 2012; Nalavany et al., 2009; 
Totsika et al. 2011a,b). Research comparing parental wellbeing among behavioral 
phenotypes has found that the association between child ID and parental well-being is 
significantly less pronounced among parents of children with Down syndrome than 
among parents of children with other diagnoses, particularly autism. Researchers have 
hypothesized that this is related to a higher level of adaptive behavior amongst 
individuals with Down syndrome and the higher prevalence of behavior problems among 
children with autism (Esbensen et al., 2010; Abbeduto et al., 2004).  
 Parents are described as using a variety of coping strategies, such as positive 
reframing, and have been identified to harbor optimism and experience hope (Hastings & 




limited research on the effect of personality and coping strategies in upholding well-being 
(Families Special Interest Research Group of IASSIDD, 2014). Because clinical trial 
participation is likely influenced by parental coping, improving understanding of the trial 
participation decision-making process may help further elucidate the role of coping in 
selecting to participate in a clinical trial and the impact of these trials on parent and child 
well-being. 
Parenting a child with Fragile X Syndrome  
 
There is also a body of literature specific to the ways parents experience raising a 
child with FXS. Fragile X Syndrome is relatively unique compared to several other 
common ID conditions due to its single gene cause and variation in phenotype. The main 
impact that this may have on parental coping and well-being is the increased likelihood 
for families to have multiple affected members, who may express different degrees and 
manifestations of outcomes. Additionally, maternal guilt over transmitting a mutation in 
the FMR1 gene may affect psychological coping and reactions to parenting a child with 
FXS (James, 2003).  
 Parents of adolescents and young adults with FXS have been observed to fare 
better (in terms of depressive symptoms and pessimism) than parents of adolescents and 
young adults with autism spectrum disorder (ASD) but worse than fathers of adolescents 
and young adults with Down syndrome (Hartley et al., 2012; Abbeduto et al., 2004). 
Additional comparisons among FXS and other conditions have suggested that parenting 
involves more challenges to maternal psychological well-being than Down syndrome and 
the combination of FXS and autism is considered to be especially challenging. More 




more pessimism about their son’s future compared to mothers of sons with Down 
syndrome. Additionally, mothers of sons with FXS and comorbid ASD were found to 
have lower levels of reciprocated closeness with their son than mothers of sons with other 
conditions (Lewis et al., 2006).  Families affected by FXS have been observed to report a 
high quality of life but particularly struggle with a lack of social support, social life, and 
parenting knowledge (Raspa et al., 2014).  
 Behavior problems and mood instability have been suggested as the most 
debilitating aspects of FXS. Examples of challenging behaviors common amongst 
affected children are tactile defensiveness, hand flapping, poor eye contact, hyperactivity, 
tantrums, perseveration, hyperarousal to sensory stimuli, impulsivity, self-injury, and 
aggression (Hatton et al., 2002; Hagerman et al., 2009; Symons et al., 2010). 
Fragile X Syndrome Clinical Trials 
 
 The past ten years have marked major progress in designing treatments for FXS. 
In the past, gold-standard medical management involves symptom management rather 
than curative therapeutics. The state of the research began to change after the mGluR 
theory of FXS was presented in 2004, raising the possibility of alternate treatment 
options. The theory postulates that the neurological deficits in individuals with FXS are 
due mainly to downstream consequences of overstimulation of the mGluR pathway (Bear 
et al., 2004).  
 The mGlurR theory has become the basis of several targeted experimental 
treatments for FXS, such as use of the mGluR5 antagonist AFQ056 (mavoglurant, 
Novartis Pharmaceuticals). In addition to the mGluR system, the GABA system has been 




other neuropsychiatric and neurodevelopmental disorders. Other experimental 
medications for FXS have targeted this system. Included in this category of drugs are 
arbaclofen (Seaside Therapeutics) and ganaxolone (Marinus Pharmaceuticals) (Lozano et 
al., 2014). Clinical trials evaluating the effectiveness of these drugs have been ongoing 
for approximately eight years (Gomez-Mancilla et al., 2014). Because behavior problems 
are often the most significant concern reported by parents, ongoing clinical trials 
evaluating the efficacy of novel FXS drugs are targeting reduction in behavior problems 
(Sansone et al., 2012).  
 For many FXS drug development trials, approximately 30% of participants 
respond well to the experimental drug. This may not be adequate to demonstrate overall 
efficacy and result in FDA approval for marketing. Currently, researchers are attempting 
to identify biomarkers (such as FMR1 gene methylation) for predicting efficacy of 
particular drugs for specific individuals (Lozano et al., 2014).  
Another barrier to trial success has been the reliance on family questionnaires 
related to the affected individual’s behavior as the outcome measure. This outcome 
measure raises concern of placebo effect, and researchers are aiming to discover more 
quantitative outcome measures that relate to central nervous system function or molecular 
changes. Additionally, the process of obtaining FDA approval for medications sometimes 
requires companies to establish safety and efficacy in adults before studying a given drug 
in children. It is speculated that reversing behavioral and intellectual abilities in FXS is 
more difficult in adults than children, and so low efficacy of adult studies prevents the 




While the advent of drug-development clinical trials has likely been a welcome 
development in the FXS community, the difficulties inherent in the process may have 
implications for parents’ expectations, hopes, and motivations. Little is known about how 
parents and children respond to these trials. Research has not yet addressed the emotional 
and physical toll of participation. 
Theoretical and Conceptual Framework 
 
Our research aimed to explore parental decision-making, motivations, and the 
overall experience with FXS clinical trial participation. These concepts were explored 
using the Common Sense Model (Diefenbach and Leventhal, 1996), Epstein and Street’s 
adaptation of Charles et al.’s Model of Treatment Decision Making (2007), and 
Hoberman et al.’s conceptual model of Factors that Influence Parental Decisions to 
Participate in Clinical Research (2013).  
Common Sense Model of Illness Representation  
 
First, Leventhal’s Common Sense Model of Illness Representation (Diefenbach & 
Leventhal, 1996) was used to inform the stress and coping context of the experience that 
will be studied. The model takes a self-regulatory approach for studying and 
understanding health behaviors, such as treatment decisions or clinical trial participation. 
It provides a model for conceptualizing stress and coping in the face of health threats, and 
thus can be used to contextualize stress and coping experienced by parents and how that 
may be affected by clinical trial participation. Our study proposed that clinical trial 
participation may be one way that parents cope with raising a child with FXS. The model 
posits that individuals are active problem solvers who perceive the reality of health 




of the model are: 1) individuals are active problem solvers both seeking information and 
acting to test hypotheses about the meaning of his or her somatic sensations and physical 
condition 2) the illness representation is the central cognitive construct that guides coping 
and the appraisal of action outcomes; 3) representations are highly individualized and 
may not be in accord with medical facts (Deifenbach & Leventhal, 1996). This study 
explored parents’ experiences of raising their child with FXS using this stress and coping 
model as a framework. The interview prompted parents to explore how their experiences 
of parenting their child affected their decision-making. Also, the interviews explored the 
effect of their decision to participate (or possibly participate) on their parenting 
experience.  
Treatment Decision Making Model  
 
Second, our conceptualization of parental clinical trial decision-making was 
informed by Charles and colleagues’ Treatment Decision-Making Model. This model 
describes a spectrum of decision-types from paternalistic (clinician decides treatment) to 
shared (clinician and patient together decide treatment), and then informed (patient 
decides treatment based on information from the clinician and other sources). According 
to this model, each type of decision-making proceeds through three stages, information 
exchange, deliberation, and making the final decision (Charles et al., 1999). Epstein and 
Street claim that ideally, even in unilaterally-made final decisions, the decision-making 
process itself should be characterized by active engagement by all parties in the 
information-exchange and deliberation stages. It also argues that the quality of the 
patient-clinician interaction, not the patient’s role per se in deciding treatment, is the 




This model assists our research as it outlines different types of treatment decisions and 
frames the decision- making process that will be explored. Specifically, the model guided 
us to explore the role of the health care provider in the decision-making process as well 
as the impact of the decision-making process on the relationship with the healthcare 
provider.  
Factors that Influence Parental Decisions to Participate in Clinical Research  
 
Finally, Hoberman and colleagues (2013) have created a model of factors that 
influence parental decisions to participate in clinical research based on prior research, 
which was used to inform the querying of such factors in our interview guide. The model 
suggests child characteristics, parental characteristics, and study characteristics to all 
together lead to parental understanding. Parental understanding is then suggested to lead 
to parental perceptions of the study, which is then suggested to lead to decision-making. 
Decision-making is considered to be modifiable by external factors, and finally, decision-
making is considered to lead to the decision to participate or not participate in clinical 





The objectives of this research were to improve understanding of parental proxy decision 
making for clinical trial participation of children with Fragile X and explore parent 
experiences of drug development clinical trials for Fragile X Syndrome. 
Aim 1: To describe the decision-making process about participating in these trials. 
In particular, we aim to capture parents’ preferences, motivations, influencing factors, 
and barriers related to trial involvement.    
Aim 2: To describe parental decisional conflict or decisional regret related to their 








 This study was carried out using a qualitative design with semi-structured 
interviewing followed by inductive coding as themes emerged. The qualitative approach 
was selected because little was known about parental proxy decision-making for FXS 
trials, or even the perceptions of drug trials amongst parents with children who have 
intellectual disability. 
The study aimed to explore the decision-making processes of parents of individuals 
with FXS surrounding therapeutic trial participation. Parents who had a child enrolled in 
a trial in the past (Group 1), and parents who have denied trial participation (Group 2) 
were interviewed.  
Recruitment and Procedure 
 
Parents were recruited from the National Fragile X Foundation (NFXF), which has 
over 1000 members, via website post and in-person recruiting at the NFXF 2016 
conference, and through FRAXA twitter and e-mail list-serv. Website posts and e-mail 
messages consisted of the recruitment letter, which is included in Appendix A. Online 
outreach was supplemented with a link to the study’s NHGRI website page. The content 
of online outreach is included in Appendix B. Parents recruited through NFXF and 
FRAXA internet outreach were provided with the e-mail contact information of the 
interviewer. Upon being contacted by interested parents, the interviewer scheduled a time 
to call each interested and eligible participant. All participant contact information (first 
name, email address, and phone number only) was kept in a confidential database, and 




conference utilized word-of-mouth and direct conversations with parents about the study, 
as well as placement of flyers around the conference center. The flyer layout is included 
in Appendix C. Parents recruited at the conference were interviewed in person when 
schedules permitted. Parents were also able to leave their contact information with the 
interviewer (CDA) if they preferred to participate in a phone interview after the 
conference. 
At the appointed time, the parents participated in a phone-based or in-person 
informed consent process (see Appendix D). Once the participant verbally consented to 
participate in the study, the interviewer proceeded with the interview, following a semi-
structured interview guide. The participant was able to request to be withdrawn from the 
study at any time up until participant identifiers were destroyed. Audiotapes of the 
interviews were transcribed by an external agency and were coded by the primary 
investigator (CDA) for thematic analysis. A second coder coded 30% of the interview 
data to assess inter-rater reliability. 
Study Sample 
 
 Parents needed to meet these criteria in order to participate in the study: 1) be a 
parent of a person (of any age) with FXS, 2) be 18 years of age or older, cognitively 
intact, and able to speak English, 3) have experience either with choosing to enroll their 
child in a drug development clinical trial for FXS in the past or declining an offer of drug 
development clinical trial participation for their child with FXS. One parent was recruited 






 Interviews were conducted over the phone and in-person depending on the 
participant’s preference and availability. In this study, 17 interviews were conducted in-
person and 17 interviews were conducted over the phone. For both in-person and phone 
interviews, parents were given a copy of the informed consent information to review on 
their own (via e-mail for phone participants, and in hard-copy for in-person participants), 
and the primary investigator reviewed its content with them prior to the interview. 
Informed consent to proceed with the interview was provided verbally by all participating 
parents. Each interview was audio-recorded and uploaded to a password-protected 
website. The recordings were transcribed verbatim and checked by the interviewer 
(CDA) for accuracy.  The semi-structured interview was first guided by 
sociodemographic questions (see Appendix E) and then by open-ended questions (see 
Appendix F) and took between 30 and 60 minutes, with an average of about 45 minutes. 
Following each interview, the interviewer (CDA) completed the interview summary form 
(see Appendix G) to capture initial reflections.  
Data Analysis 
 
Coding   
 
The interviews were coded to identify common and interrelated themes supported 
by a software program, NVIVO. A set of preliminary codes based on a priori topics was 
applied to several initial transcripts, and concurrently, a set of emerging codes was 
identified and included in the codebook. Codes continued to be added until no text was 
identified that could not be coded using the established codes. Interviews were coded 
concurrently with data collection and early interviews were re-coded using the final 




An initial codebook including the following preliminary themes was refined 
throughout coding the initial transcripts: expectations, motivations, and hopes of parents 
related to trial participation, parent decision-making type (i.e. shared, informed, 
paternalistic, as framed by Charles et al. 1999), parent decision-making influencing 
factors (informed by Hoberman et al., 2013), parent decision-making barriers, and 
parental regret or satisfaction level with the decision they made or with their decision 
making experience. The final codebook is included in Appendices H through K.  
A second coder coded ten randomly selected interview transcripts, representing 
about 30% of the total data, to establish reliability. An inter-rater-reliability Kappa score, 
calculated based off of ~10% of the total data (3 of the 10 second-coded interviews), 
yielded 0.85 suggesting good reliability of the coding. 
Thematic Analysis  
 
Coded findings were interpreted via thematic analysis. This approach identifies 
common themes and explores each theme in detail. Transcribed data was read and reread 
to promote overall familiarity. Codes were collated into potential themes, and all data 
relevant to each potential theme was gathered. Potential themes were reviewed in relation 
to coded extracts and the entire data set. Clear definitions and names for each theme were 
developed to refine the specifics and the overall narrative. The selection of vivid, 
compelling illustrative quotes and final analysis of these extracts enabled relation back to 
the research question and literature in the final stage of analysis. Finally, this process 
generated the results, which are described using conceptual systems and an overarching 



















































 Thirty-four parents participated in the study. Sixteen of the participating parents 
were interviewed about their experience with choosing to have their child enrolled in 
drug development clinical trials in the past (Group 1), fifteen of the participating parents 
were interviewed about their experience with declining drug development clinical trials 
(Group 2), and three parents who were deliberating the possibility of future clinical trial 
participation for their child and did not meet the criteria for either of the two groups were 
also interviewed. Tables 1 and 2 describe the socio-demographic and relevant medical 
characteristics of the participants in Groups 1 and 2 respectively. The majority of 
participants were female, married, and white. All of the parent participants were the 
biological parent of the affected child except for one adoptive mother. Some parents had 
more than 1 child with FXS, and were guided to focus on one affected child for whom 
they have considered trial participation for the interview. The participating parents’ 
children ranged in age from 20 months to 32 years old, and ranged in severity of FXS 
symptoms from mildly affected to severely affected by parent report.  
 Parents in Group 1 had experience participating in several trials, including 
Seaside STX209 or Arbaclofen, Novartis AFX056, UC Davis Sertraline, UC Davis 
Minocycline, Roche RO4917523, UC Davis/Marinus Ganaxolone, Alcobra MG01C1, 
and Neuren NNZ-2566. Six parents in Group 2 had experience declining specific trials, 
including Seaside STX209 or Arbaclofen, UC Davis Sertraline, and Alcobra MG01C1. 
Nine parents in Group 2 had experience declining several trials generally and did not 




Table 1. Sample Characteristics, Group 1, (n=16)  
 









Biological Mother Carrier Status Pre-mutation (≤ 200 repeats) 
Untested or unknown 




Education Highest Degree Completed 
High School Degree 










Race  White or Caucasian, Non-Hispanic  





Total Number of Children in Family 2 or more children 13 (81) 
Number of Children affected by FXS in Family 2 or more children with FXS 4 (25) 












Affected Child Age At Time of Interview Child (0-13 years) 
Adolescent (13 years-18 years) 




Affected Child Age At Time of Trial Participation Child (0-13 years) 
Adolescent (13 years-18 years) 















Table 2. Sample Characteristics, Group 2, (n=15) 
 
Sociodemographic characteristics  n (%) 








Biological Mother Carrier Status Pre-mutation (≤ 200 repeats) 
Untested or unknown 




Education Highest Degree Completed 
High School Degree 










Race  White or Caucasian, Non-Hispanic  





Total Number of Children in Family 2 or more children 12 (80) 
Number of Children with FXS in Family 2 or more children with FXS 3 (20) 












Affected Child Age At Time of Interview Child (0-13 years) 
Adolescent (13 years-18 years) 




Affected Child Age At Time of Trial Decline Child (0-13 years) 
Adolescent (13 years-18 years) 















Table 3. Sample Characteristics, Interviewees in neither group, (n=3) 
 
Sociodemographic characteristics  n (%) 








Biological Mother Carrier Status Pre-mutation (≤ 200 repeats) 
Untested or unknown 




Education Highest Degree Completed 
High School Degree 










Race  White or Caucasian, Non-Hispanic  





Total Number of Children in Family 2 or more children 3 (100) 
Number of Children with FXS in Family 2 or more children with FXS 1 (33) 












Affected Child Age At Time of Interview Child (0-13 years) 
Adolescent (13 years-18 years) 





 Our interviews uncovered five major themes; motivations, contextual decisional 
factors, trial-specific decisional factors, decision making process, and decisional conflict 
and regret. 
Motivations Behind Choice to Participate or Decline 
 
 Parents were asked to reflect upon what ultimately motivated them to either 
decline or elect participation in a drug development clinical trial. Parents in Group 1, who 
had chosen to enroll their child in a drug development trial for FXS, described two major 
motivations to elect participation. Some were motivated only by their belief that by 




symptoms (Group 1 n=5). Others were motivated by this chance of individual benefit as 
well as altruism in benefitting the entire FXS community (Group 1 n=11).  
I was motivated by those possibilities that he could sit in his classroom and learn to read, and just 
pay attention to what was going on. Because I think if he was able to sit still long enough, he 
could get so much more. Because he gets a lot now, just in passing. If he was able to actually sit 
through an instruction, it would just be amazing. (Mother 015, Group 1) 
Again, really just what motivated me was the potential outcome. And, honestly, even knowing that 
if he got a placebo, just the fact that, by and large, this study could obviously help the whole 
Fragile X community. So I also was realistic knowing that even if he got a placebo, that even by 
participating, we were still kind of giving back. Moving the science forward. (Mother 033, Group 
1) 
 
Parents in Group 2, who had declined trial participation for their child with FXS, 
mentioned a range of motivations to decline, including poor match between trial outcome 
and their child’s particular symptomatology (Group 2 n=5), logistical inconveniences 
(travel, scheduling, or number of appointments) (Group 2 n=5), blood draw requirements 
(Group 2 n=2), inability for their child to remain on their regular medications throughout 
the trial (Group 2 n=3), low perceived likelihood of long-term access to the experimental 
drug (Group 2 n=3), general attitudes against medicating their child for FXS symptoms 
(Group 2 n=4), and concern around the risks of the trials (Group 2 n=3). 
 Ultimately I’ve become very particular about the outcome and if the outcome they are measuring 
is not a high priority for us then I decline them. It has to be related to what is very important to us. 
(Mother 028, Group 2) 
 I was motivated to decline ultimately because of travel. And number of visits. I guess, it would 










Table 4: Group 2 Major Reasons for Declining 
 
Participant ID Number Major Reasons for Declining  
001 Blood draw requirements, inability for child to remain on regular 
medications throughout trial, and low perceived likelihood of long-term 
access to the experimental drug 
002 Poor match between trial outcomes and particular child symptomatology 
003 Blood draw requirements and inability for child to remain on regular 
medications throughout trial 
005 Excessive travel to trial site and high number of required visits 
007 General attitudes against medicating child’s FXS symptoms, excessive 
travel to trial site and high number of required visits, and low perceived 
likelihood of long-term access to the experimental drug 
008 Excessive travel to trial site 
009 Concern around risks and safety  
014 Concern around risks and safety, general attitudes against medicating child’s 
FXS symptoms 
016 Difficulty in scheduling trial-related appointments 
018 Inability for child to remain on regular medications throughout trial 
024 General attitudes against medicating child’s FXS symptoms 
025 General attitudes against medicating child’s FXS symptoms, concern around 
risks and safety, poor match between trial outcomes and particular child 
symptomatology 
026 Poor match between trial outcomes and particular child symptomatology and 
low perceived likelihood of long term access to the experimental drug 
028 Poor match between trial outcomes and particular child symptomatology  
031 Excessive travel to trial site 
 
 
Contextual Factors Impacting Decision Making 
 
 Several background contextual factors specific to the participating parents, their 
parenting experience, and their child were reported as influencing the parents’ decision 
making about clinical trial participation. Most frequently, parents reflected on their 




conceptualizations of their child’s personality, and the fit between clinical trial 
participation and their child’s particular symptomatology and age.  
 
Attitudes about Medications to Treat Symptoms of FXS 
 
 General attitudes toward medication use to treat symptoms of FXS were reported 
by parents as shaping their attitudes about participation in clinical trials (n=21). Parents 
of children with FXS held a range of attitudes about medicating their child. Some 
decliners shared only negative past experiences with medications and skepticism around 
medicating their child for FXS symptoms (Group 1 n=0, Group 2 n=5).  
 Because he was developing and still growing, I did not want medication to interfere with that 
development. That he needed to learn how to live in his own body with who he was. (Mother 025, 
Group 2) 
Other parents only described medication use positively (Group 1 n=6, Group 2 n=2), 
sharing past experiences in which they believed medication improved their child’s quality 
of life or was an integral component of caring for their child. One parent described 
medication as a tool to unlock the potential of children with FXS:  
You know, with Fragile X, if you can just take care of the anxiety, the distractibility and certain 
things, then they’re free to be able to be so much more, and that’s the thing about the drugs. It just 
makes it possible for them to reach their potential and to be themselves, you know, and do things, 
and do the therapy they’re in. (Mother 013, Group 1) 
Other parents described mixed views of medications—perceiving both negative and 
positive aspects (Group 1 n=3, Group 2 n=3). A subset of these parents described their 
first time choosing to medicate their child as being most challenging:   
 I wasn't even giving my son medicine. It took me a while before I said, ‘Okay, you need to start 
medicating him.’ So I fought that medicine and, ‘No, you're not medicating my child,’ for a very 
long time. So when I did, my doctor actually congratulated me and was like, "You're probably one 
of the first persons that waited until your child actually really, really needed the medicine and 




Attitudes about Research 
 
 Parents described their general attitudes towards biomedical research with most 
parents (n=19) sharing positive opinions of research. Those who felt positively about 
research described participation as an opportunity to learn more about their child, FXS, 
and other related or co-morbid conditions. They also saw research participation as an 
opportunity to contribute to what is known about FXS in hopes of improving care and 
information quality for themselves as well as the community broadly.  
I would hope that parents would get more involved, you know, because sometimes that will open 
up opportunities for you to participate and to contribute. And I do think participating in research 
will give you a better opportunity to understand the disorder and your child as well. (Mother 029, 
Group 1) 
The minority of parents (Group 1 n=1, Group 2 n=3) who shared apprehension about 
research was afraid of the notion of their child being used as a ‘guinea pig’ or a ‘test 
subject,’ coupled with the unknown risks of experimental drugs.  
I was very scared about anything, any medicine, and putting her, feeling like she’d be a guinea pig 
with medicine. The medicine thing and side effects and what it could mean especially when people 
don’t know. That’s why they’re testing it, and I really was repelled—actually, that’s a strong word 
but resistant always for that for years. (Mother 013, Group 1) 
 
Symptomatology of Affected Child 
 
 Parents who perceived their child as mildly affected and those who thought of 
their child as severely affected incorporated the symptomatology of their child most into 
their consideration of drug development clinical trial participation. Parents of mildly 
affected children described more apprehension around trial participation than parents of 
severely affected children. They were concerned that experimental drugs would 
detrimentally affect their child’s development and described feeling satisfied with 




affected children felt that their child could contribute to scientific knowledge about FXS, 
and that their child had a level of functionality that would make participation less 
burdensome compared to families with more severely affected children. 
Considering the gains that we would make compared to the gains that a child that was extremely 
low functioning would make, in our minds the researchers would probably not suggest the trial for 
the benefit of our child (Father 007, Group 2) 
Because he was so high functioning there was great interest. It is a bit of a funny story with one of 
the researchers examining our son. We thought there was great interest to see how the trial would 
benefit a child that was already quite verbal just to see where it would take it on that level (Mother 
002, Group 2) 
He's my little experiment. Because I want to help him, and because he will let them take blood. 
Because we started doing that when he was little. And because we were going there for blood 
since he was four years old, he is not one of those kids that you have to nudge and tousle to get 
blood from. (Mother 034, Group 1) 
Parents of severely affected children expressed interest in FXS medication development, 
but also described being more frequently ineligible for studies and less able to participate 
compared to parents of mildly affected children due to greater caretaking demands 
(Group 1 n=0, Group 2 n=2). 
I think -- I believe, honestly, that most trials look at people who are more -- higher than on the 
lower end. Sometimes I feel like we're left out. But I feel like, too, you should be trying to help the 
lower-end ones more because they're the ones that's struggling and don't have the capability of 
doing certain things. (Mother 014, Group 2) 
Unfortunately, he is more affected than the vast majority of kids with Fragile X.  It wouldn't have 
been fair, to my son, to put him through a trial. He already has enough issues navigating life and 
trying to stay sane. And honestly, the people who would've gone with him -- me, his dad, 
whomever, it wouldn't have been fair to us, either, to try and, you know, make ourselves go 
through that because it would've been ugly. (Mother 031, Group 2) 
 
Age of Affected Child  
 
 The age of the affected child appeared to play a role in a parents’ deliberation of 




more apprehension towards clinical trial participation due to anxiety surrounding the 
potential of an experimental medication to interfere with their child’s development and 
have long-term negative ramifications (Group 1 n=0 Group 2 n=2).  
They're growing and developing and here you're introducing these chemicals into their body and 
you don't know the impact on development. (Mother 024, Group 2) 
Parents also viewed the age of their child as affecting the likelihood that a successful 
targeted treatment for Fragile X Syndrome would be of benefit to their child. Most 
parents of older children shared pessimism that a targeted therapeutic would be effective 
for their child, and explained that such a medication would most likely be effective for 
affected infants and toddlers treated earlier in their development (Group 1 n=1, Group 2 
n=3).   
I don’t think that a cure is going to come around with enough time for my son to benefit from it. I 
think it’s more complex than it will take to fix in the next, even ten or fifteen years and I worry that 
as somebody with Fragile X gets older, when you start reversing that, what happens to them? I 
think the older you get, probably the more difficult it is to relearn or to readjust so I just don’t see 
it happening in his lifetime. I see all these studies trying to impact young children and babies. I 
think finding a cure is critical, it absolutely has to be done but it’s not going to affect my family to 
any great degree. (Mother 028, Group 2) 
Even if we were able to do gene replacement, and we popped in a new copy of the gene, his brain 
would probably have so much catching up to do with a typical developmental process that he 
probably would always have a little trouble functioning himself in the real world. He’ll probably 
always be a little mentally impaired even if gene replacement were to land on our doorstep like 
today. You just kind of get set in your ways, get used to doing things a certain way, and your brain 
kind of forms around that, so it’s not just this gene and just these proteins affected. You know, 
their whole brain is kind of formed around that way they learned it. (Mother 032, Group 1) 
 
Effects of FXS on Parental Conceptualization of Child’s Personality 
 
 The majority of interviewed parents found many personality strengths to be the 




strengths most commonly attributed to the syndrome were their child’s ability to express 
love (Group 1 n=8, Group 2 n=3), overall happiness (Group 1 n=6, Group 2 n=5), 
kindness and compassion (Group 1 n=4 Group 2 n=6), and sense of humor (Group 1 n=4, 
Group 2 n=7).  
Your life will be more enriched because of a person with Fragile X. You know, really get to know 
them. You know, laugh with them. They're really funny... Spend a little time each day viewing life 
through their eyes because they live in a pretty nice world. They see nice people. Everybody in 
their -- you know, for the most part, everyone they meet is nice. They don't see a mean person. 
(Mother 001, Group 2) 
 
Despite feeling these characteristics to be part of their child’s FXS, most parents 
did not perceive these personality strengths to be threatened by a potential or existing 
experimental drug. When they considered how a hypothetical successful targeted 
treatment for FXS would change their child’s life, nearly all interviewees in both groups 
explained that their child would become happier and more functional versions of 
themselves. 
I think that if there were a drug that helped that would mean he would be able to learn more. That 
doesn’t mean that he would turn on a dime and suddenly not be him. I think it would be just 
wonderful to help him explore the world.  (Mother 003, Group 2).  
He would be able to communicate with us more. He would be able to communicate with other 
people who don’t know him. He would- I think he would still be this fun-loving guy, but we would 
probably get more out of him and understand. I know what his wants and dislikes are, but he 
would be able to actually communicate to us, even if he couldn’t talk and he was able to use a 
communication device better than what he is doing now, meaning that he could actually put a 
sentence together, that right there would be a milestone in itself. (Mother 014, Group 2) 
A small subset of parents (Group 1 n=0, Group 2 n=2) perceived that their son’s FXS 
symptoms may benefit his existing quality of life, implying that a targeted therapeutic 




It’s hard to say what it would be for my son. Would it be unnatural? All of a sudden, he starts 
understanding things, he can make connections and grow, you know, as a person? I don’t know, I 
couldn’t because I don’t live in his head.... Would it be a good thing for him to all of a sudden be 
able to see the world for its good and bad? I don’t know. I mean, he’s lived his whole life being 
looked after and living in his little world and he’s happy most of the time. It’s like one of those 
questions where a person who’s lived their life deaf and wanted to know what it’s like to hear and 
others don’t. (Mother 005, Group 2)  
These interviewed parents described a theoretical concern that was outweighed by their 
desire to remove the limitations of FXS from their son’s life, enhance their ability to 
connect with their son, and enrich his life experience.  
I would seriously go for a cure anyway because our selfish perception is, “I want what I think is 
best.” I want what I think is best for my child. It’s like “what if my child really is happy?” What if 
he says, “Mom, why’d you take the blindfold off? I was so happy, and now, you know -- I 
understand, but it’s not as great as you thought it was going to for me.” You have that 
philosophical side to it, but then, of course, you have the side where you want to be able to have 
deep conversations and make sure that they are conscientious, and that they are aware of how the 
world works so that they can protect themselves, that they can go out and be the most that they 
want to be and support families if they want to start families, and have deep relationships and 
whatnot. (Mother 025, Group 2) 
  
A minority of parents did not find anything “beneficial” or good about their 
affected child’s FXS (Group 1 n=3 Group 2 n=0).  
 I don’t think there’s anything beneficial about Fragile X. (Father 004, Group 1) 
I can’t think of any beneficial aspects of Fragile X. I would think that if he didn’t have to deal with 
this pest, that he would be a much happier person, and so would I for him. So, I do not see any 
benefit to his illness. (Mother 030, Group 1) 
 
Trial Specific Decisional Factors  
 
 In addition to discerning the characteristics and needs of their child in conjunction 
with their beliefs about FXS, medications, and research, parents also assessed trial 




mechanism, expectations and hopes for the trial, barriers and inconveniences of the trial, 
trial phase, perceived trial purpose and risks, and their degree of trust in the researchers 
and clinicians involved in the trial. 
Purpose of Trial 
 
 The purpose of the clinical trial, as perceived by the parents, was found to be 
another important decisional factor as they considered trial participation. Parents 
described the purpose of trials to be to develop a drug that would reduce specific FXS 
symptoms. The most commonly described purposes of trials were to treat all FXS 
symptoms and develop a cure (Group 1 n=4, Group 2 n=7), treat anxiety (Group 1 n=7, 
Group 2 n=5), improve attention and focus (Group 1 n=3, Group 2 n=3), modify behavior 
(Group 1 n=7, Group 2 n=7), enhance cognition and learning (Group 1 n=5, Group 2 
n=2), enhance language and communication (Group 1 n=3, Group 2 n=4), and better 
social skills (Group 1 n=2, Group 2 n=3).  
 Parents frequently used the trial’s purpose in evaluating the degree to which they 
felt it matched their child’s particular symptomatology (Group 1 n=5, Group 2 n=10). 
Parents were more interested in trials that they believed were targeting symptoms that 
their child particularly struggled with. Parents who declined trials frequently cited a poor 
match between the trial’s ‘purpose’ and their child’s symptomatology as a significant 
factor in their decision to decline. 
I thought it would probably increase his communication ability for sure. But, the enabling of more 
fluency and maybe some easier communications, we were doing just fine and we were making 
progress. it wasn’t a trial with an outcome ultimately that hit the target of the kind of result that 




The purpose of the trial was to see if the medication will work for the targeted symptoms that my 
adult child had. The social anxiety and anxiety around loud noises, new situations. (Mother 017, 
Group 1) 
 
Experimental Drug Mechanism 
 
 Parents were aware of the genetic cause of FXS and the efforts to develop a 
therapeutic targeted at the disease mechanism, likely due to the presence and outreach of 
disease community-based research funding (FRAXA). Several parents commented on the 
drug mechanism as an important aspect of trials they had considered, and felt more 
interested in trials that were evaluating drugs involved in the mGLUR and GABA 
systems (Group 1 n=5, Group 2 n=4). They felt that these targeted experimental 
medications were more likely to have a dramatic effect on FXS symptomatology than 
other medications designed to interfere at the symptom-level rather than the syndrome-
level.  
I was led to participate by the positive outcomes that others had already experienced, the fact that 
there were such amazing results in some of the laboratory studies, the non-human clinical trials 
that had come before, and the fact that this drug targeted a known deficiency in his body, and so 
that we felt like it was -- it made sense to us. (Mother 012, Group 1) 
It was a very promising medication that was really -- it was the first of its kind, I guess, at the time 
-- that was actually targeting the disease process, not just the symptoms. And seeing that my son is 
on quite a bit of medication, we were excited that this was something that could really get to the 
mechanism, the functioning in the brain. (Mother 021, Group 1) 
Trial Expectations 
 
When asked to recollect and delineate their hopes (what they wanted to happen) 
and expectations (what they thought may happen) from the time of decision making, 
many parents specified a FXS symptom that they expected would improve for their son 




child’s speech and language skills (Group 1 n=2, Group 2 n=2), focus and attention 
(Group 1 n=1, Group 2 n=1), learning and cognition (Group 1 n=0, Group 2 n=1), 
behavior (Group 1 n=0 Group 2 n=2), and anxiety (Group 1 n=2, Group 2 n=0). The 
symptoms that they expected to see benefit infrequently overlapped with their perceived 
target outcomes of the trial they were considering.  
I expected that this would decrease my son’s anxiety. I expected that going to new places and 
maybe doing new things would not be as anxiety-provoking. I expected that we might see an 
increase in his academic performance. (Mother 012, Group 1) 
I expected that there would be an improvement in the ability to communicate on the expressive 
side and that that would create more social and educational opportunities for him. (Mother 002, 
Group 2) 
We expected improvements in language and socialization. We did not expect a miracle from this. 
But we expected some type of marginal but measurable improvement. (Father 004, Group 1)  
 
Other parents often described lacking any specific expectations of individual 
benefit for their child (Group 1 n=11, Group 2 n=2). Many parents described 
purposefully not forming expectations around individual benefit due to their awareness of 
the possibility that their son could receive a placebo rather than the experimental drug, as 
many of the trials parents had considered were double-blind.  
It was hard to form expectations because we didn't know if he would actually be on the medication 
or not. (Mother 006, Group 1) 
We went in with very -- no expectations, because we don’t know if you’re getting a placebo, what 
you’re getting. (Mother 019, Group 1)  
I went in to it with no expectations and I realize that’s the double-blind placebo and my chances 
are we would get the placebo, so I had no expectations. (Mother 027, Group 1) 
 
A small subset of these parents shared their lack of expectations of individual 
improvement to be based upon an understanding that experimental drugs inherently lack 




Well, I knew it was a trial, so I knew either it would or would not have any effect on his thinking 
or his abilities. (Mother 017, Group 1) 
Some parents who lacked expectations for direct immediate trial benefit to the child did 
expect the trial to be successful in resulting in an approved effective medication for FXS.  
Yeah, I really didn’t have any, because it had been explained to me that we could be on a placebo, 
so I really wasn’t looking for anything, and then -- but I did expect that the drug was going to be 
approved. I was really pretty – I mean, I think all of us had really thought this drug had been 
vetted and was safe and that it was going to be approved, so that was an expectation that I had, 
that when the trial would be over that we would be taking this medication because we could get it 
prescribed. (Mother 032, Group 1)  
 
 Yet another common expectation of drug development clinical trials described by 
parents was a direct non-specific positive effect on their child’s FXS symptomatology 
(Group 1 n=3 Group 2 n=5). These parents were hesitant to define exactly what they 
expected to change, or how much they thought something would change, but were clear 
that they thought some aspect of their child’s symptoms would noticeably improve.   
I expect for something positive that's going to change physically or emotionally. I mean, that's 
what I would expect from a trial. I want to see something in everyday life change. (Mother 014, 
Group 2)  
I was pretty sure we were going to see something. I wasn’t too concerned. I was more curious to 
see what we were going to see. (Mother 032, Group 1) 
 
 A small subset of parents, mostly comprised of decliners, expected negative 
outcomes from the trial; that the experimental drug would be ineffective or have side-
effects (Group 1 n=1, Group 2 n=3). 
I didn’t think it would work. I thought it would actually cause side effects whether it be seizures or 






Trial Hopes  
 
 Overall, parents spoke more about their hopes for the trials than their 
expectations, having an easier time describing them. While parents’ hopes often 
overlapped their expectations, they were more specific or grandiose. Similar to their 
expectations, parents most frequently hoped for improvement in specific FXS symptoms 
that their child struggled with, however they frequently hoped for a more dramatic 
change than they expected. Parents in both groups hoped that trial participation would 
result in significant positive changes in their child’s learning and cognition (Group 1 n=9, 
Group 2 n=3), anxiety (Group 1 n=8, Group 2 n=4), attention and focus (Group 1 n=4, 
Group 2 n=1), behavior (Group 1 n=4, Group 2 n=4), social skills (Group 1 n=4, Group 2 
n=2), and speech and language (Group 1 n=4 Group 2 n=5).  
 Well, I hoped it might improve language. One of the things that I know for certain about those 
with intellectual disabilities is that they can learn, and they can learn when they’re adults, and 
learning might be much slower but they can learn. So of course, we were hopeful. Maybe, whether 
or not it would suddenly enable our son to speak, it nevertheless might have encouraged him to 
communicate more. (Father 004, Group 1) 
I just expected his ability to communicate to improve in some way. Well, in the perfect world, he’d 
wake up talking to me. That’s what I hoped for. Like, it was all up there and he just couldn’t get it 
all out. (Mother 005, Group 2)  
A group of parents in both groups hoped that the experimental medication would prove to 
be a cure for FXS (Group 1 n=4 Group 2 n=2).  
And my hope was that we’d participate in the trial, he’d be getting the drug, and it would do far 
more than anybody ever expected it would do, and it would basically cure him, and he would come 
up to me, we’d have a normal conversation like I have with my other children, and then he would 
have to be pulled out his special needs school because it wasn’t appropriate any more unless he 
needed to catch up. Yeah, and I’d hire tutors to catch up to his normal grade level and that instead 
of having to have him watched, he could start helping me watch the younger children and that he 
would become a fully functioning, normal 16-year-old. And if he wanted to go outside, he’d get a 




The hope is, you know, the expectation for a drug as I said, like say the goal of it was to replace 
the FMRP Protein and then essentially take away the effects of Fragile X. (Mother 24, Group 2) 
So the hope is that we would see what my son might look like if really Fragile X could be 
eradicated or reduced. Or taking whatever function he had and really amp it up to see what he is 
fully capable of with this adjunct therapy. (Mother 021, Group 1) 
 
Barriers to Participation 
 
 Parents in both groups discussed several barriers to participating in trials. Many 
were logistical inconveniences, such as excessive travel to the trial site (Group 1 n=8, 
Group 2 n=7), high number of required trial appointments (Group 1 n=5, Group 2 n=5), 
difficulty with scheduling trial appointments (Group 1 n=2, Group 2 n=1), and challenges 
with taking time off of work to monitor their child throughout the trial and facilitate 
participation (Group 1 n=1, Group 2 n=3).  
It would be a lot better if these trials could be managed locally. If the chosen handful of trial 
centers could monitor the programs, but have it administered by your local physicians. I think that 
would be a big deal. Listen, we didn’t have to stay in hotels, but, you have a choice. You’re trying 
to drive seven or eight hours all in one day, or is it an overnight trip. If you have other children, 
you have to make arrangements for them. It became a very trying experience, the actual trial. 
(Father 004, Group 1) 
It typically required travel, and numerous overnight stays for evaluation that just never really fit 
into our lifestyle. (Father 007, Group 2) 
Certainly we did consider having to disrupt not only his school schedule a little bit but our family 
schedule because we were running to Rush quite a bit. As I mentioned that’s a day for us. Three 
hours down, appointment, three hours back, that sucks up a good day (Mother 028, Group 1) 
 
 Another frequently mentioned barrier to trial participation was the necessity of 
blood draws (Group 1 n=9, Group 2 n=4). Many parents felt that their child struggled 
significantly with having blood drawn, and some felt it was traumatic for their child. 
Blood draws were also described as being difficult for the phlebotomists and the parents, 




parents declined any trial that involved blood draws, and others described it as the 
primary aspect of trial participation that they did not like.  
The main thing is that if it involves blood work, I didn't even -- I mean, that was my first question. 
Does it involve blood work? If it did, I didn't even consider it. (Mother 001, Group 2) 
Another one of my big issues with clinical trials is my son will not tolerate blood draws. And so I 
will not put him through that PTSD of having a blood draw. It's very traumatic for him. (Mother 
024, Group 2) 
The only part of participating that I was unsure about was the required blood draws, because of 
the trauma that that causes for my son. (Mother 027, Group 1).  
 
 Some parents were concerned about trial requirements to discontinue use of 
regular medications throughout the trial period (Group 1 n=3, Group 2 n=4). A subset of 
these parents was unable to participate in a trial due to significant concerns about taking 
their child off of medications, such as seizure medications.  
When we found out what was involved, making the decision about the trial was excruciating. That 
was pretty awful. They are on a lot of medication. With our son, it was going to take three months 
to wean him off his current medication before we could even get to participate. And then he was 
going to have to be off of everything for a certain amount of time. And then we could get the 
medication, whether it was real medication or not. We would have to take them out of school, 
because they couldn’t function. We wouldn’t be able to go anywhere because we couldn’t 
guarantee their safety anywhere. That was really scary. This is back to the beginning, when my 
son would throw himself down in the parking lot and scream and cry. And I’d worry about him 
hitting his head on the cement, not to mention that it’s a hundred degrees -- you can fry an egg on 
the sidewalk. So, are they going to be hit by cars? You just can’t guarantee their physical safety. 
So that was a huge concern. Was I going to have to quit my job and stay home with them? What 
we were going to live on if I had to quit working? So there would be all this time to wean them off 
the medication, and then there would be all this time with no medication, and then we wouldn’t 
know -- it would be like six weeks we would possibly be on the placebo and we’re getting nothing. 








Risks of Trial 
 
 The most commonly described anticipated risks of drug development clinical 
trials were physical side effects (Group 1 n=14, Group 2 n=13). Some parents described 
risk of unknowable side effects, while others were aware of specific side effects that they 
perceived to be associated with the experimental drug in question. Concerns about side 
effects were a significant deterrent from trial participation for parents in both groups.  
 There's always a side-effect with medication and so, those were the risks we were most concerned 
about. There were not really any specific side effects we were worried about. We were worried 
just generally. (Mother 006, Group 1) 
I guess there were always the unknown risks of a medication. I don’t think I knew of any specific 
risks.  (018, Group 2) 
I wasn’t really for it because, down the road, you just never know. After you put that in your body, 
over time, you just never know. Down the road they might say -- I mean I hate to say this because 
it can happen with anything, I mean anything you do in life you take a chance. But, down the road 
they could say, “Well, that drug now causes seizures, or causes cancer, or causes kidney failure.” 
So I really didn’t want to try it. (Mother 026, Group 2) 
 
Many of the parents in Group 1 considered risk of side effects to be low despite 
mentioning them as the main risk of participation (Group 1 n=8), while many of the 
parents in Group 2 considered side effect risks to be more severe (Group 2 n=9).  
It had that B vitamin thing, and all that and stuff I had heard about that they were wondering was 
doing good, but the side effects that they were seeing was real mild, so it was like the risk factor, 
for me, was so low that I said, “I can do this one.” (Mother 013, Group 1) 
And knowing that it was based on a med that’s already on the market and used since the 1920s, I 
felt that the risks of side effects were very minimal. No worse than some of the medications he’s 
taken on the market now. (Mother 029, Group 1).  
So, the one thing about minocycline that you don't really hear much about, and I've actually 
spoken with my son's dermatologist about is that extended use of minocycline can cause graying of 
the mouth and even the face. It’s been – it’s permanent. I actually spoke with his physician about 
that one time. Even as an adult, not just graying of the teeth. We're talking graying of the inside of 
your mouth and of your actual face -- the skin on your face. So, I know that that's a risk. (Mother 





A subset of parents were concerned about the inability of their child, due to age and/or 
symptomatology, to communicate pain or discomfort indicative of a side-effect or 
adverse reaction to the experimental drug (Group 1 n=1 Group 2 n=4).  
And then they're not really able to tell you if they're uncomfortable, if they don't have that 
language capacity already. And so it was hoping that we would notice if there was anything 
wrong. (Mother 008, Group 2) 
 
Phase of Trial  
 
 Overall, parents were found to have a low level of concrete understanding about 
the phases of drug development clinical trials. Accordingly, the trial phase was not a 
primary decisional factor. When asked what they thought about phases of trials, parents 
believed that the phase was related to the age range of participants (Group 1 n=5, Group 
2 n=5), whether the trial was determining safety (Group 1 n=7 Group 2 n=4), whether the 
trial was determining efficacy (Group 1 n=5, Group 2 n=2), whether or not participants 
had the target disease (Group 1 n=1, Group 2 n=2), whether or not participants may 
receive a placebo (Group 1 n=3, Group 2 n=7), and the FDA approval process (Group 1 
n=5, Group 2 n=6).  
So I think in -- yeah, I don’t know. So my understanding is that in phase one, maybe it’s adults. 
Yeah. And I know that they check for signs and symptoms and different things like that, and side 
effects. Then I think -- yeah, I don’t know. Phase two, I think, is maybe more people; I don’t know. 
Yeah, I don’t know. (Mother 012, Group 1) 
To me, phase III meant that it was safe. And that there was some idea that, in his dosage range, 
they would get some sort of result, measurable results. (Father 004, Group 1) 
Phase one is the initial phase for toxicity. Phase two is an initial trial for efficacy, and then phase 





You know, that's a good question because I don't know what phase 2 means. I think that means 
that it's been -- I don't know whether it's been tried in animals, or in typical people. So, that's a 
good question. I don't know. (Mother 001, Group 2) 
I don’t know much about how phase works because I’ve never participated in it. (Mother 026, 
Group 2) 
The phase of the trial was very important, however, to a subset of parents. These 
interviewees were hopeful that participation in a phase two or three trial would mean that 
the experimental drug would likely be FDA approved and available long term for their 
child (Group 1 n=6, Group 2 n=0). 
We agreed to do this trial because it was in phase three. Because we were told that, like everyone 
else, that once the trial was over we would get the medication if it helped our son. That was my 
biggest deciding factor and why we decided to do the trial. (Mother 019, Group 1) 
I think it was second phase and I knew that if it worked out or if we had enough information right 
after the study that the drug might actually go on, it could actually get approved by the FDA. 
(Mother 017, Group 1) 
 
Trust in Trial Personnel and Institutions 
 
 Fifteen parents described their degree of trust in the personnel and institutions 
involved in the trial (researchers, clinicians, clinics, and pharmaceutical companies) to be 
a significant decisional factor as they considered drug development clinical trials for their 
child with FXS. Parents in both groups who had negative experiences with having their 
child in a drug development trial in the past felt their trust in these personnel and 
institutions had suffered as a result.  
We are living in times where every institution that we’ve come to depend on has not just 
disappointed us, but it’s just outraged us. And there is no trust in anything. (Father 004, Group 1) 
Then there’s the trust issue, you know? Lay it on us. I want the good, the bad, and the ugly 
because if there’s not that presented in the way that’s expected then there’s no trust. Especially 
when it’s -- you’re also learning. You’re new enough or newer to this realm and feeling that 
you’re not as experienced and don’t know enough to make a properly informed decision. (Mother 





Some parents in Group 1 explained that their high level of trust in the researchers and 
clinicians involved in the trial, based on long-term relationships with the trial site or 
awareness of the head researcher’s work, strongly influenced their decision to participate.  
I really just spoke to the clinical trial doctor, and the woman I knew from the Elwin group was 
actually, I think, the study manger, so I had already known her as well. Which was nice, so that 
kind of gives a comfort level. (Mother 033, Group 1) 
I think it was just that we trusted the process. We trusted our doctor who was involved in the 
study. (Mother 021, Group 1) 
 
Decision Making Process 
 
 Parents were asked to reflect on their decision making process around drug 
development clinical trial participation. As they considered their decision making 
process, most parents remarked on weighing the risks and benefits of the trials. Family, 
friends, and health care providers were found played roles in the decision making process 
for interviewed parents.  
Weighing the Risks and Benefits  
 
 Parents in both groups assessed their perceptions of the potential risks and 
benefits of the trials in making the ultimate decision whether to enroll their child. Parents 
in Group 1 tended to feel that the potential benefits outweighed the potential risks, while 
parents in Group 2 tended to feel the opposite.  
 You know, it’s like anything else. You just -- do you think we should this? As I said, we thought -- 
we saw little or no risk so based on that and based on a possibility that it might do something 
good, we went forward with it -- the decision. (Father 004, Group 1) 
Anytime anything will benefit our children, we lean toward that automatically. So, the decision, 
once we looked at the risks and the benefits, and the potential for other children with Fragile X, it 
was easy to make a decision to participate. We felt like the risks were minimal compared to the 
benefits. (Mother 006, Group 1) 
When you’re deciding, you really need to take the time, like, really weigh out all the pros and cons 




have to really weigh out “is the possible benefit definitely more than the possible risk that is 
involved?” and if you can say yes to that, if your child is, very regressed or on the low end or 
whatever, then “okay, I think it’s worth the risk if the benefit is there,” if this means my child can 
speak and my child can go to the bathroom on their own, my child can interact with other people, 
if that’s worth “oh, my gosh, my child now has a problem with their kidneys” or whatever. I really 
have to weigh it out. (Mother 025, Group 2) 
 
Roles in the Decision 
 
Most parents described making clinical trial decisions primarily alone or with the 
support of their partner. Parents found informational support in the researchers and 
clinicians involved in the trial (n=13). Most interviewed parents were notified about trials 
remotely, through support group e-mails or mailed flyers from clinics. They would 
deliberate the trial independently, and reach out to the researchers and clinicians involved 
in the trial for more information as needed.  
It’s probably a conversation with my husband. Like when I say probably, the fact that I was the 
one bringing him in, it was more -- it was a joint decision between my husband and I, but it is 
probably more on me, because I was the one committing to bring him in and everything. (Mother 
33, Group 1) 
The clinic doctor explained what was involved and sent the information. And we had talked about 
it and stuff. She expressed excitement about it, but she did not push me into doing it. (Mother 003, 
Group 2) 
I talked to his doctor, and he said he thought it would be okay.  I talked to the doctor who ran the 
study; I called to him first and he explained what it was and what it would target.  I think I read a 
little bit online about this study.  Talked about it with my husband, asked my son and he said he 
would be fine with it, he would do it.  And after that, we were in. (Mother 017, Group 1) 
Many parents did not feel that any health care providers played a significant role in 
influencing their decision. In particular, several interviewed parents described their 
child’s primary care physician, pediatrician, or psychiatrist to play no role in the clinical 




adequate knowledge about FXS to contribute significantly to the decision, and described 
instances in which they had to educate this doctor about FXS in the past.  
 I'd probably talk to his psychiatrist about it, and just say, “I'm thinking of doing this. What do you 
think?” And see what she says. I mean, I'm the one educates her about Fragile X and so, she 
would probably be fine with whatever I said. But it would be just another view point. It’d be 
another source of information.  I might talk to his primary doctor, but he's just a primary doctor. I 
mean, we just go to him for earaches, headaches. Kind of like I would say to his psych, I would 
just use her as a source of information but she wouldn't, at this point, help make the decision. My 
husband and I would. (Mother 001, Group 2) 
I don't know that our day-to-day treaters -- pediatricians, internists -- would be qualified. And I 
don't know that I would take much of what they had to offer, because we know more than they do. 
(Father 009, Group 2) 
Nobody helped me make the decision. The doctor, she gave me information (Mother 013, Group 1) 
It’s really pretty much been myself, because, to tell you the truth, so many doctors don’t even 
know much about Fragile X. I probably know more about it then the doctor. (Mother 026, Group 
2) 
 
A subset of parents reported that other parents of children with FXS played an 
important role in their decision-making process, as they consulted with parents who had 
experience with some aspect of the trial, such as the experimental medication or the 
primary researchers (Group 1 n=5, Group 2 n=4). 
Listening to other people like, my Facebook community is a lot of parents who have children with 
Fragile X Syndrome. So we always discuss different topics and different things, and that's opened 
my eyes a lot, like, okay, the trials might be worth it. And that's why I have been looking into them 
way more than I had and seeing that it's not going to hurt him. Like, it's not going to be this 
painful thing or anything like that. So if you ask me today, I'm actually willing to give a trial some 
consideration as long as I know that it's not going to physically hurt him. (Mother 014, Group 2) 
We talked to everybody and anyone who was on the trial. “What are you seeing? What is it doing? 
What is it like?” I would say honestly the major thing was hearing from other people that it was 





Parents were also asked whether their child with FXS played a role in the decision. 
Nineteen parents representing both groups felt that their child played no role whatsoever 
in the decision-making process. Their child’s lack of influence in the decision-making 
process was attributed to their child’s inability to understand, either due to their young 
age or degree of affectedness.  
My son’s role is very minimal because he's too little to really understand the concept of a clinical 
trial. (Father 010, Group 1) 
He doesn’t have the cognitive ability to make any decisions. (Mother 027, Group 1) 
The remaining parents described ways that their child with FXS played a role in the 
clinical trial decision-making process, however most of these roles were limited. Parents 
reported that their son with FXS played a role in the decision in relation to one aspect of 
participating, such as travel, acceptance of taking medications generally, or 
communicating pain or discomfort that could be indicative of side effects.  
My son played no role. Except indirectly. Just judging how he felt about clinical trials. I almost 
considered doing it because he had enjoyed the process. So he’d probably like doing it again. But, 
yeah he didn’t have much of a role because he can’t express himself that way. (Mother 003, Group 
2) 
Well, I asked him, does he want to go back and forth or not? At first he said yes. And so, that’s 
when I said yes because he did. For the second trial, at first he said yes but then I started talking 
to the manager of the study, and she couldn’t be very flexible with the times and it was just too 
hard to try and get everyone’s schedule to wrap around her schedule, which was inflexible 
basically. (Mother 016, Group 2) 
 
Decisional Conflict and Regret  
 
 Overall, parents expressed a range of conflict but low regret about their clinical 
trial decisions. Sixteen parents found making the decision relatively easy compared to 
other decisions in their lives (Group 1 n=10, Group 2 n=6). Parents who found the 




potential positives of participating and cited very few negatives (Group 1 n=10) or were 
parents in Group 2 who expressed strong beliefs against medicating their child (Group 1 
n=0, Group 2 n=3), or cited disinterest in the experimental drug’s mechanism (Group 2 
n=3). 
The decision was pretty simple. Based on what it was doing, they weren’t doing anything like a 
medical and if there were some type of adverse reaction, we would just immediately have to stop. 
And it’s kind of -- it’s a lot of pressure as [a single person], because I have to make all those 
decisions, and I don’t have somebody to kind of throw it back and forth with. But other than that, 
just the fact that it could not only help him, but that this study could also help other people that 
have younger children. Maybe it helps, and then it can help them. (Mother 015, Group 1) 
It has always been a really easy decision for us because we’ve never really had the desire – seen 
the need or had any desire to start him on any medications. So that made the decision pretty easy 
to not participate (Father 007, Group 2) 
 
Another group of interviewees found the decision to be hard (Group 1 n=4, Group 
2 n=6). These individuals were often focused on risks and barriers that prevented them 
from participating despite a desire to do so. Six parents reported finding the decision to 
be moderately difficult - not particularly hard or easy (Group 1 n=3, Group 2 n=2).  
It was moderately difficult to make the decision. Easy because I was so eager to find help for him 
and I wanted to find a drug that could possibly help. Hard were the side effects and possible mind-
altering state they kept on talking about. (Mother 017, Group 1) 
It was difficult for me to not participate because they’re making progress in this area, like huge 
progress. I think about when this was discovered and it hasn’t been that long and they’re on drugs 
that they want to try on individuals with it. I’m very excited to hear that things are happening that 
fast. I wish that we could participate. (Mother 005, Group 2) 
 
All parents in Groups 1 and 2 reported feeling as though they made the right 
choice given what they knew at the time. Even when the trial experience was challenging, 
or the experimental drug was ultimately determined to be ineffective, parents in Group 1 




that they made the right choice because their participation helped move the science 
forward, and they often perceived benefits of participation outside of the effects of the 
drug, such as learning more about their child or gaining access to resources and 
information.  
Oh, no doubt. Of course I feel I made the right decision. Because I loved the changes I saw in him. 
So, he didn’t walk in totally cured. I loved the subtle changes, and that gave me a glimpse of what 
the future could look like. I had to moderate what I was hoping for, but when I got through that, it 
definitely gave me a glimpse of what the future could look like. And then the other thing is that I 
just felt good about having participated, because I know how important it is. Without clinical 
trials, you don’t get drugs on the market. (Mother 032, Group 1) 
Well, because even though the study failed, I feel that there was a lot of good information gleaned 
from the million parent surveys that we filled out and the blood draws, not just from my son, but 
from all of the participants. And anything that we can do that adds to their body of knowledge 
about Fragile X and can possibly lead to other, more successful drug trials, then that’s not wasted 
effort. (Mother 012, Group 1) 
Yes, I feel I made the right decision. Because in the end it didn’t work out, and it was taken away 
from everyone. (Mother 018, Group 2) 
I think I made the right decision and that's been reinforced by other people that I've talked to who 
have been on those trials and the money was pulled and they saw great things happening from 
being on those medications and then the drug companies said, "due to funding we're not going to 
be able to continue with this medication or pursuing it." And the family was devastated. Because 
they felt like they had finally gotten their son and gotten to know who he was and then they were 
taken off and they were devastated. And so for me, I was like that's exactly what I expected and 
that's exactly -- that was pretty painful for them. Extremely painful. Like I don't think they'll evert 
trust anybody with Fragile X research again. Like the foundation, or the drugs, or any of it. They 














  Overall, parents of children with FXS report deliberating a number of factors 
throughout their clinical trial decision-making process. Our study revealed that parents 
assess these factors by weighing the potential risks and benefits of participation, and seek 
informational support from clinicians and researchers involved in the trial. This decision 
making process leads these parents to their decision, to either enroll their child in a trial 
(constituting parents in Group 1), or decline to do so (constituting parents in Group 2). 
Decisional conflict ranged among parents regardless of group, with some finding the 
decision-making process to be difficult, and others finding it to be easy. Despite the 
degree of difficulty involved in making a decision, upon reflection, all parents in our 
study ultimately reported feeling that they made the right choice for their family and did 
not feel regret. 
The identification of specific factors involved in parental decision-making for 
FXS clinical trials can be used to generate hypotheses for future quantitative research 
aimed at measuring the effect of these factors on the decision making process and 
outcomes such as decisional conflict. These downstream studies can then provide the data 
for designing evidence-based interventions to facilitate the decision making process.  
 
Decisional Factors and Process 
 
 Prior research has identified contextual and trial-specific decisional factors for 
pediatric clinical trial participation for physical health conditions (asthma, sickle cell 
disease, and vesicoureteral reflux) (Barakat et al., 2013; Hoberman et al., 2013). Our 




with FXS consider as they deliberate trial participation. In general, parents in our study 
had strong attitudes about medicating their child for FXS, and these attitudes appeared to 
influence decision making about drug development clinical trial participation. Some 
parents who had declined trial participation were found to avoid medication for FXS 
symptoms altogether, while on the other extreme, some parents who had elected trial 
participation were found to embrace it as a critical component of caring for their child. 
While drug development for rare diseases frequently encounters barriers in recruitment 
due to relatively small study populations, the variance observed in our study around the 
FXS community’s interest in medication may constitute another barrier in acquiring 
adequate numbers of clinical trial participants for this disease context.  
Furthermore, as parents with strong positive attitudes towards medication are 
more interested in participating in drug development trials, their child is likely to already 
be on medications. Our study revealed difficulty in ceasing use of medications 
throughout the duration of the trial, with some parents who had declined participation 
citing this challenge as a primary motivation to decline. Future drug trials could benefit 
from minimizing time off medications and communicating clearly about this need to 
parents. 
As FXS is primarily psychological and cognitive rather than physically disabling 
or life-threatening, parents appear to be more risk averse to medication side effects and 
drug development clinical trial risks compared to what has been observed in parents of 
children with life-threatening progressive conditions (Peay et al., 2014). As parents of 
children with FXS struggle with managing their child’s condition in many ways, some 




situation to that of parenting a child with a life-threatening chronic condition) in their 
coping processes, and expressed particular gratitude for the physical health of their child. 
Prior research has characterized the use of downward social comparison in coping with 
chronic health conditions (Arigo et al., 2014). Parents of children with FXS may be 
particularly resistant to any risk of harming their child’s physical health as social 
comparison may be one way they cope effectively. Parents of children with life-
threatening conditions, conversely, are faced with relatively little to lose in this domain, 
and medication side effects may be perceived as less harmful for their child when 
compared to the untreated disease course.   
 Our interviews also revealed the potential benefit of the drug to be a primary 
decisional factor for parents of children with FXS considering clinical trials. This is 
consistent with prior research exploring decisional factors involved in parental decision 
making for pediatric clinical trial participation for physical ailments (Barakat et al., 2013; 
Hoberman et al., 2013; Markward et al., 2013). In our study, we found that parents who 
had both declined participation and elected participation evaluated the potential benefit of 
the drug through their perception of the drug’s mechanism of action and the degree of 
match between the purpose of the trial, which they described as developing a drug that 
would reduce specific FXS symptoms, and their child’s particular symptomatology. To 
determine this match, parents generally considered what they were struggling most with 
in caring for their child. For example, parents who were raising a child who is nonverbal 
frequently mentioned higher interest in trials with communication as the target symptom, 
and parents who were raising a child who was exhibiting violent behaviors sought trials 




individual benefit from the drug, based on drug mechanism and degree of match between 
target symptom(s) and child symptomatology, formed hopes and expectations for the trial 
for parents in both groups, as well as the primary motivations behind electing 
participation amongst parents who had elected participation for their child. Some 
decliners cited a poor match between their perception of the trial’s purpose and their 
child’s symptomatology as a primary motivation for their declining participation. 
 Consistent with prior research in other disease contexts (Peay et al., 2014; Jansen 
et al., 2011), there was evidence of therapeutic misinterpretation in our study. The 
expectations of parents who had elected participation were often high and described in 
terms of potential for individual benefit. The purpose of trials was also generally 
described in terms of individual benefit rather than an effort to contribute to scientific 
knowledge. Nevertheless, parental understanding of trial goals was expressed in the 
interviews, as we also observed altruistic motivations and perceived participation benefit 
in contributing to scientific knowledge amongst parents who had elected participation.  
In line with prior work (Peay et al., 2014; Weinfurt, 2003; Jansen et al., 2011), 
our observation of therapeutic optimism and misinterpretation seems to be a result of 
parents’ emotional engagement with trials, and dissonance between cognitive and 
emotional understandings. Past research has suggested phase 1 clinical trial expectations 
to be related more strongly to personality variables (such as high trait optimism) than 
knowledge about clinical trials (Weinfurt, 2003). Furthermore, psychology research has 
uncovered the relevance of unrealistic optimism in clinical trial decision-making. 
Unrealistic optimism, when one thinks that one is more likely to experience positive 




cognitive and affective determinants. In a study of patients enrolled in early-phase 
oncology trials there was no significant relationship between unrealistic optimism and 
misunderstanding about the purpose of clinical trials, and more participants exhibited 
unrealistic optimism than therapeutic misconception. Thus, optimistic biases are 
understood to be an independent explanation for patients’ expectation of therapeutic 
benefit from clinical trial participation that is not reliable on lack of knowledge or 
misconception (Jansen et al., 2011), and is a likely explanation for the therapeutic 
misinterpretation observed in our study.  
 The logistics of participation constitute an additional major decisional factor for 
parents considering clinical trial participation. This has been observed in previous work 
evaluating the decisional factors involved in pediatric clinical trials for physical 
conditions (Barakat et al., 2013). Our study revealed several barriers to participation that 
could prevent parents from electing to participate despite their hopes for a highly 
beneficial drug. Most prominently, parents who had declined trial participation were 
deterred from enrollment when the trials involved a greater burden on their time, through 
excessive travel to the trial site or high number of required appointments. In addition, 
parents of children with FXS are highly concerned about the necessity for blood-draws in 
trials, as it is common for affected children to be resistant to having blood drawn. 
Perceived risks of side effects constituted another barrier to participation, with parents of 
severely affected or young children expressing particular concern that their child would 
be unable to communicate pain or discomfort indicative of side effects. The presence of 
these barriers constituted the most common motivations for declining trial participation 




These findings have many practical implications for the design of future drug 
development clinical trials for this rare disease. Our study revealed a need for FXS 
clinical trials to feature an increased number of clinical sites with better distribution 
across the country and minimization of appointments and blood-draws required for 
families where possible. Additionally, the concerns of parents with young or severely 
affected children around their child’s ability to communicate pain or discomfort 
indicative of side effects should be addressed in future trials. For example, parents may 
be educated about nonverbal signs of pain or discomfort, assured that clinicians involved 
with trials will know how to assess pain and discomfort for all participants, provided 
guidance in teaching their children to use communication aides, or reassured that the 
study’s evaluations would involve monitoring for side effects.  
 Overall, our study suggested parents’ decision making processes to involve a 
weighing of these decisional factors, framed as potential risks and barriers and potential 
benefits of participating. Parents in both groups primarily made these decisions either 
alone or with the support of their partner. Only clinicians directly involved in the trial 
were mentioned as providing significant informational support. Parents did not feel that 
their child’s primary doctors were qualified to assist with clinical trial decisions, and the 
only friends that were involved in the decision were other parents of children with FXS.  
Consistent with previous work that evaluated parental ratings of affected 
individuals’ ability to consent for clinical trials (Bailey et al., 2014), a significant portion 
of parents felt that their child was not at all capable of participating in the trial decision 
making process, and the vast majority of remaining parents found their child to have a 




Decisional Conflict and Regret 
 
 Our study was also able to describe levels of parental decisional conflict and 
regret over the drug development clinical trial decision making experience. Decisional 
conflict was found to range in both groups from low to high, with some finding the 
decision to be easy, some finding it to be hard, and others finding it to be moderately 
difficult. Those who found the decision to be easy were more often parents who had 
elected participation and were focused on the potential positives of participation or were 
parents who had declined trial participation and hold strong beliefs against medicating 
their child. Those who found it to be a hard decision were often focused on the presence 
of barriers or risks that conflicted with their desire to participate. This contrasts with prior 
qualitative research in Duchenne muscular dystrophy, which observed low decisional 
conflict overall, with most parents finding trial participation to be a ‘non-decision’ (Peay 
et al., 2014). This difference is likely to be due, in part, to the fact that DMD is a 
progressive, fatal disorder. In addition to these differing emphases of decisional factors, it 
is possible that parental personality traits influence decisional conflict levels.   
 Decisional regret was found to be remarkably low in our study. This is consistent 
with prior research that found low decisional regret amongst parents who had elected to 
enroll their child in Duchenne muscular dystrophy trials (Peay et al., 2014), as well as a 
systematic review of the extent and predictors of regret in health decisions (Perez et al., 
2016), which concluded decisional regret to be low for most health decisions. Because 
the ability to experience decisional regret relies upon individuals understanding of the 




possible that low decisional regret is the result of parents’ inability or psychological 
resistance towards perceiving this counterfactual. 
Implications for Future Research   
 
 This qualitative study has generated hypotheses that can be explored in future 
research.  First, a quantitative survey study involving a larger sample of parents of 
children with FXS (representing both participants and decliners) should query the 
primary decisional factors that were revealed in this study; parental attitudes towards 
medicating their affected child, perceptions of the potential benefit of the drug for their 
child (including the degree of match between the trial’s target symptom(s) and the 
particular symptomatology of the affected child, and parental perceptions of the drug’s 
mechanism of action), and the presence of identified barriers to participation (i.e. 
logistics and blood-draws). Quantifying these factors in conjunction with decisional 
outcomes such as conflict and regret, and additional parental characteristics, such as 
personality traits, will allow further elucidation of the ways they influence the decision 
making process, the ultimate decision, and these outcomes. Such a study may also 
examine the impacts of affected children, health care providers, and other parents of FXS 
in influencing parental trial decisions.  
 Further research should assess the effectiveness of decisional interventions, such 
as shared decision-making counseling interventions with health care providers or 
decision-aides to be completed by the parents independently. These aides are used to 
clarify the decision-maker’s weighing of potential benefits and barriers or risks involved 
in the decision, and could be informed by the specific decisional factors identified in our 




clarify parental feelings about these factors may assist them throughout their process of 
identifying the best choice for them. 
 Finally, parental perceptions of the likelihood for development of a remarkable 
disease modifying or curative therapy should be explored further. Our interviews 
revealed a history of high community hopes and subsequent devastation with the abrupt 
termination of several trials due to failure to meet outcome measures or loss of funding 
despite parental perceptions of benefit. Further understanding of this experience and its 
effect on the broader community will enhance understanding of parental decision making 



















 This study has several limitations. First, participants were recruited from the 
support groups, the National Fragile X Foundation and the FRAXA Research 
Foundation. Therefore, this study is limited by selection bias as participants recruited 
from these organizations may have access to more resources than the general population 
of parents of children with FXS, and thus have an enhanced ability to consider trials 
regardless of participation barriers (although our data do not seem to indicate this). 
Participants who are active with these support groups may also be relatively well adapted 
to life as a parent of a child with FXS, and have higher family functioning, both of which 
may influence clinical trial decision-making. Due to FRAXA’s investment in developing 
a cure for FXS, participants recruited through this group may hold extreme views about 
the potential for the development of a disease-modifying therapy and the meaning of drug 
development clinical trial participation. Second, our study is limited by self-selection 
bias, as participants who expressed interest in our study may over-represent the parents 
who are most comfortable with their trial decisions and accordingly more willing to 
discuss their decision-making experience in an interview, or most passionate about the 
choice they made. Our sample may have also underrepresented parents who are not 
interested in or distrustful of researchers. 
Third, participants may have been motivated to answer interview questions in 
ways that are most socially accepted or desirable rather than expressing their true 
thoughts and emotions. Fourth, recall bias is a significant limitation, as many participants 
were reflecting on decisions that occurred years ago. Participants were only able to 




limited by what they preferred to recall. Furthermore, many participants in Group 2 did 
not recall the specifics of the trials they had experience with declining. This has limited 
our ability to draw some conclusions from the decliners we interviewed, and causes 
























 The experiences reported by parents in this study raise important clinical 
implications for healthcare providers working with parents of children with FXS. Drug 
development research has permeated FXS support group environments, and parents are 
facing continued clinical trial information and invitation. Clinicians and support group 
personnel may discuss the primary decisional factors uncovered in our study with parents 
of children with FXS regardless of whether a particular trial is being deliberated. Parental 
clarity around these decisional factors may enhance parental decision making processes 
and reduce undesirable decisional outcomes, such as regret and conflict. Open 
communication and information exchange with healthcare providers is likely to assist 
parents as they navigate these environments.  
Furthermore, connection between parents of children with FXS has been revealed 
to be important in parents’ decision making process, as other parents of children with 
FXS were found to play significant roles in the decision for many interviewees. Clinics 
can facilitate and encourage these connections but also make sure they are informed, 
using high-quality educational materials directed to an informed lay audience. Our study 
also revealed a low level of understanding of clinical trial phases and true purposes. This 
warrants effective educational intervention from health care providers as needed.   
 There are also implications for healthcare professionals working with parents of 
children with autism or intellectual disability, as these disease contexts share many 
commonalities with FXS. Specifically, our findings around parental attitudes towards 
medication, relative risk aversion compared to parents of children with physical or life-




process may apply more generally to ID. Some of our findings may be more specific to 
FXS. For example, it is likely that parental perceptions of drug mechanism of action is 
likely to play a decisional factor for parents of children with FXS but not parents of 
children with ID generally, as all parents of children with ID are not unified by a single 
disease mechanism.  
In the event of drug development clinical trial invitation for parents of children 
with these more common conditions, healthcare professionals may elicit discussions with 
these parents around the decisional factors uncovered in our study, provide patient 



















 This study described parental decision making for FXS clinical trials. Our 
findings revealed primary decisional factors that these parents weigh in their decision 
making process, and explored the decisional outcomes of conflict and regret. Parents 
primarily consider their background attitudes towards medication, the potential for 
individual benefit from trial participation (through evaluating the drug’s mechanism of 
action and the degree of match between the trial’s target symptom(s) and their child’s 
specific symptomatology), and the presence of specific logistical barriers and side effect 
risks in their drug development clinical trial decision making process. The potential for 
individual benefit from trial participation largely shaped parents’ expectations and hopes 
for the trial, leading to high therapeutic optimism amongst parents who had elected 
participation. Our findings shed light upon parental proxy decision making for clinical 
trial participation in the disease context of intellectual disability, and generated 
hypotheses for future quantitative studies aimed at ultimately developing interventions to 












APPENDIX A: RECRUITMENT LETTER 
 
Dear community members, 
  
We are seeking parents of people with FXS to participate in a research study on parental 
experiences and decision-making about FXS drug-development clinical trials. The goal 
of this research study is to explore the personal story of parents who have experience 
with FXS drug-development clinical trials. 
  
Little is known about how parents make decisions about these trials, or how the trials 
impact the experience of parenting an individual with FXS. We hope this study will 
provide insight into the needs of parents who are making these decisions or are currently 
participating in a trial so that better care can be provided in the future.  
  
The study involves phone interviews with a parent of an individual with FXS. Each 
interview will last about 30-45 minutes long and involve questions about the experience 
of making a decision about clinical trial participation or the experience of clinical trial 
participation itself. We will also collect general demographic information.  
  
If you are a parent of someone with FXS (of any age), you can take part in the study if: 
-You are 18 years of age or older and speak English. 
-You have a child who was enrolled in a drug-development clinical trial for FXS in the 
past OR… 
-You have declined an offer of drug-development clinical trial participation for your child 
with FXS 
  
Out of respect for volunteering time for the interview, participating parents will be sent a 
$15 Target gift-card. 
  
If you are interested in participating in the study or would like more information, please 
contact the research fellow, Celeste Schepp D’Amanda, by e-mail. Thank you for your 
time and consideration to take part in this study. We look forward to hearing from you.  
  
Sincerely,  
Celeste Schepp D’Amanda, BA 
Research Fellow 
JHU/NHGRI Genetic Counseling Training Program 
celeste.d’amanda@nih.gov  
  
Barbara Biesecker, PhD 
Principal Investigator  







APPENDIX B: RECRUITMENT WEBSITE 
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Fragile X Syndrome Clinical Trials: Expectations, Hope and Decision Making of Parents
We invite you to participate in a research study on how
parents of people with fragile X syndrome (FXS) experience and
make decisions about FXS drug development clinical trials. The
goal of this research study is to explore the personal story of
parents who have experience with FXS drug development clinical
trials.
Little is known about how parents make decisions about these
trials or how the trials impact the experience of parenting an
individual with FXS. We hope this study will provide insight into
the needs of parents who are making these decisions or are
currently participating in a trial so that better care can be
provided in the future.
The study involves phone interviews with a parent of a person
with FXS. Each interview will last about 30-45 minutes and involve questions about the experience of making a decision about clinical trial
participation or the experience of clinical trial participation itself. We will also collect general demographic information.
If you are a parent of a person with FXS (of any age), you can take part in the study if:
You are 18 years of age or older and speak English.
You have a child who was enrolled in a drug development clinical trial for FXS in the past OR ...
You have declined an offer of clinical trial participation for your child with FXS OR ...
You are currently considering drug-development clinical trials for your child with FXS.
Out of respect for volunteering time for the interview, participating parents will be sent a $15 Target gift card.
If you are interested in participating in the study, or would like more information, please contact the research fellow,
Celeste Schepp D'Amanda, by email.

































APPENDIX D: INFORMED CONSENT SCRIPT 
 
Parental Experiences of FXS Drug Development Clinical Trials  
INFORMED CONSENT  
 
First, we would like you to know that:  Taking part in this research study is entirely 
voluntary. You may choose not to take part, or you may stop being in the study at any 
time.  
 
The purpose of this study is to help researchers learn more about the experience of 
parental decision-making about drug-development clinical trial participation for their 
child with FXS. Our goal is to identify the needs of parents in this situation and improve 
care for future parents.  
 
You have been asked to join this study because you are a parent of an individual with 
FXS and you have experience with drug-development clinical trials for FXS.  
 
You can take part in the study because   
-You are 18 years of age or older and speak English 
-You have a child previously enrolled in a drug-development clinical trial for FXS 
or  
-You have declined clinical trial participation for your child with FXS.  
 
The study involves a phone interview that will last about 45 minutes. The interview will 
be tape-recorded. All identifying information will be removed from written transcripts of 
the interviews. We will also collect general demographic information.  
There are no physical risks of taking part in this study. However, it is possible that some 
questions may make you feel upset or anxious. If you should feel upset at any point 
during the research interview, you may stop participating. If you feel upset after 
completing the interview, you may contact the researchers.  
 
There are no direct benefits to you from taking a part in the study. However, the 
information you provide to us may help improve our understanding of the experience of a 
parent of an individual with FXS. We may be able to use this to inform future studies that 
aim to improve the process of clinical trial decision-making.  
 
You are a volunteer in this study and may stop it at any time. During the interview you 
may also choose to skip any question that you do not wish to answer. If you decide to 
stop being in the study during your interview, all of our collected information about you 
may be permanently destroyed. After the interview is complete, we will not be able to 
destroy the information from your interview.  
Once you are enrolled in the study you will be assigned a unique participant ID number. 
This ID number and not your name will be used on forms with the information we 
collect; all paper forms will be accessible only to the researchers. Audiotapes will be 




such as names and specific locations will be removed or changed. We will not share any 
identifiable responses with outside parties.  
 
 
Do you have any problems or questions about this study or about your rights as a 
participant?  
 
If you agree to the terms of the study and are willing to participate, you may proceed to 
verbally consent. Your consent means that you have been informed of the study’s 
purpose, its procedures, and the possible risks and benefits. Your consent means that you 
have been given a chance to ask questions before you consent. Your consent means that 




















First I would like to obtain some information about you and your family.  
Are you a father or a mother of a son with Fragile X syndrome?  
 
Are you your son’s biological or adoptive parent?  
 
For biological mothers- what do you know about your FMR1 carrier status?  
 
How much formal schooling have you had?  
 
Did you finish high school? College? Professional School?  
 
How do you define your race?  
 
Are you married?  
 
How many children do you have?  
 
Briefly tell me about all the trials you have decided about. [Review list of considered 
clinical trials.]  
 
How many of your children have FXS?  
 
How many of them have participated in a clinical trial?  
 
For how many of your children have you considered clinical trials?  
 
 
How many times have you considered enrolling each son in a trial (go through each child 




Do any of your adult relatives have Fragile X syndrome?  
 
 










What do you consider the most challenging or hardest aspects of your child’s FXS?  
What do you consider the most beneficial or best aspects of your child’s FXS?  
How do your child’s FXS symptoms compare with other children you know with FXS? 
 
Overall Parenting Experience 
 
When did you first realize FXS was in your family?  
When did you first learn that your son (or daughter) had FXS?   
Can you recall what your responses were to learning the information?  
What thoughts did you remember having about it then?  
What feelings did you remember having about it then?  
How did these thoughts and feelings change over time?  
What has been challenging about being a parent of someone with FXS?  
What has been beneficial or good about being a parent of someone with FXS?  





Perhaps you have considered clinical trial participation for your son more than once. Or 
maybe you have had more than one of your sons involved in clinical trials for FXS.  
For this interview, I will ask you to focus on one time when you considered enrolling 
your son in a clinical trial for FXS. Please pick the time when you were considering 
having your son participate in a clinical trial for FXS that stands out most to you in some 
way, had the greatest impact on you, or perhaps was the most challenging.  
 
Tell me a little about the trial decision you made this time. What made it have a big 
impact on you?  
For this trial decision, how old is your son with FXS for whom you were considering 
clinical trial participation?  
How old was he back when you were deciding about having him involved in a clinical 
trial?  
How many clinical trials has your nuclear family participated in related to FXS?  
How many clinical trials has your nuclear family participated in related to FXTAS?  
What phase was the FXS trial that we are focusing on for this interview?  
What do you think about the phase?  
What do you feel about the phase?  
What do you think is (or was) the purpose of the clinical trial?  
What do (or did) you think researchers and doctors thought the drug might do?  
What do (or did) you think the drug might do?  
What do (or did) you think were the risks of being in the trial?  




What did you think it would mean for your son if the trial was successful? 
 
[Prompts for those whose trial was terminated] 




Tell me the story of how you first learned there were drug development clinical trials for 
FXS.  
For the clinical trial decision that we are focusing on for this interview, was there only 
one trial you were deciding about, or were you selecting from several options?  
What has it been like (or how was it) to make a decision about having your child in the 
clinical trial?  
What is (or was) your decision-making process like?  
Who, if anyone, helped you make the decision?  
What role did your child’s doctor have in your decision-making process?  
What role did family or friends have in your decision-making process?  
What role did your son with FXS have in the decision-making process?  
What are aspects of the trial that are leading you (or lead you) towards (or away from) 
participating?  
What is influencing you (or influenced you) to participate (or not participate)?  
What are aspects of the trial that you did (or do) not like?  
 
I’m going to ask you to think about two different things. One is what you expected or 
actually thought would happen from the trial, the other is your hopes or what you wished 
or wanted to happen from the trial.  
Starting with what you actually thought would happen from the trial- what expectations 
do you (or did you) have for the trial?  
What hopes do you (or did you) have for the trial?  
What motivates you (or motivated you) to participate (or not participate)? 
 
Decisional Conflict or Regret 
 
Some decisions are relatively easy to make and others are much harder – how easy or 
difficult was it for you to make the decision? 
What made it easy or difficult?  
How unsure were you about the decision (or how unsure are you)?  
How clear did (or does) the best choice seem?  
How aware of your choices do (or did) you feel?  
How aware do (or did) you feel about the benefits and risks of the trial?  
Do you feel you made (or are leaning towards) the right decision?  
Why or why not?  
Do you feel satisfied about your decision making process (or your decision)?  
Why or why not? 
 





If you were giving advice to another parent of a son with FXS who is deciding about 














































APPENDIX G: INTERVIEW SUMMARY FORM 
 
Participant ID Number: ___________ 
 
Participant type: Group 1   Group 2   Group 3 
 




Date of Interview: ___________ 
 
Interview Start Time: ___________ 
 
Interview End Time: ____________ 
 






Interview Question(s) Most Responsive To: 
 
 
Interview Question(s) Least Responsive To: 
 
 





















APPENDIX H: CODEBOOK – CONTEXT  
CONTEXT  
 Advocacy in child’s care  
 Age of child  
o Adult  
o Child  
o Infant  
 Attitudes about research  
o Altruism  
o Endorsing or positive  
o Skeptical or negative  
 Attitudes about medications  
o Skeptical or negative  
o Endorsing or positive  
 Child needs  
o Academics  
o Anxiety  
o Attention  
o Behavior  
o Cognition  
o Developmental Delays 
o Language  
o Motor Skills 
o Socialization  
o Vocation or Independence  
 FXS & Personhood  
o A person, not a disability 
o Affectionate and loving 
o Determination 
o Forever child 
o Happy 
o In the moment 
o Kindness and empathy 
o Nothing beneficial about FXS  
o Sense of humor 
o Intelligence  
o Smile 
o Social skills 
 Symptomatology  
o Autism  
o High Functioning / Mildly affected  
o Moderately Functioning / Moderately affected  
o Low Functioning / Severely affected  
 Nonverbal  
o Seizures  




APPENDIX I: CODEBOOK - CURE 
 
CURE  
 Anticipating a cure  
 Cure vs. Treatment 
 Not anticipating a cure  


















APPENDIX J: CODEBOOK – DECISIONAL FACTORS  
 
DECISIONAL FACTORS AND PROCESS  
 Ability to exit trial  
 Coerciveness  
 Drug access  
o Access post trial  
o Access without trial  
 Drug mechanism  
 Expectations  
o Access to drug post trial  
o Contribute to science 
o Improvement in learning ability  
o Improvement in anxiety  
o Improvement in behavior  
o Improvement in cognition 
o Improvement in focus & attention  
o Improvement in language  
o No expectations  
o The drug would not work  
o Organized trial participation process  
o Placebo effect 
o Receive results 
o Side effects  
o To be able to perceive efficacy or placebo status  
o Vague positive effect  
 Hopes  
o Improvement in academics  
o Improvement in anxiety  
o Improvement in attention or focus 
o Improvement in behavior  
o Improvement in cognition  
o Cure  
o Improvement in education and learning  
o Improvement in functioning  
o Improvement in ability to form friendships  
o Improvement in child’s general quality of life  
o Ultimate reduction in overall medication use  
o Improvement in speech  
o To lead to approval of drug 
o Non-specific improvement in some FXS symptom(s)  
 Inconvenience  
o Blood draws  
o MRI  
o Number of appointments 




o Taking time off work  
o Travel to the trial site  
 Jadedness  
 Making an informed decision 
 Motivation  
o To decline  
o To enroll or consider enrolling  
 Phase  
o No understanding of phase  
o Phase related to age range of participants  
o Phase related to disease status of participants 
o Phase related to demonstrating efficacy 
o Phase related to placebo 
o Phase related to FDA approval and access to drug  
o Phase related to safety  
 Placebo  
 Purpose of trial  
o Improvement in all FXS symptoms and develop a cure 
o Improvement in anxiety  
o Improvement in attention and focus  
o Improvement in behavior  
o Improvement in cognition  
o Collect data and move science forward  
o Demonstrate efficacy  
o Interact with disease mechanism 
o Improvement of language and communication  
o Improvement in education and learning  
o Match between purpose and child needs  
o Demonstrate safety  
o Improvement in social skills  
 Ability to remain on regular medications  
 Risk  
o Exacerbate a FX symptom 
o Lose access to the trial drug  
o No risks  
o Risk of altering child’s life or personhood  
o Risk of getting a placebo 
o Risk of burden and inconvenience  
o Risk of side effects  
 Child’s inability to communicate side effects  
o Risk of stopping regular medications  
o Risk that the drug will do nothing beneficial  
 Risk versus benefits analysis of trial decision  
 Roles in decision  
o Role of child in trial decision  




o Role of friends and family in trial decision  
 Other than spouse, no role  
o Role of physician  
 No role  
o Role of researcher in decision  
o Physician-researcher 


















APPENDIX K: CODEBOOK – TRIAL RESULTS AND EXPERIENCES 
 
TRIAL RESULTS AND EXPERIENCES  
 Advocacy for child in clinical trial context  
 Betrayal  
 Decisional conflict  
o High  
o Low  
o Middle  
 Decisional regret 
 Drug company  
o Alcobra 
o Neurin 
o Novartis  
o Seaside  
 Drug Name  
o Arbaclofen  
o Lovastatin  
o MDX 
o Baclofen 
o Minocycline  
o Sertraline  
o STX209  
o AFQ  
 Effect of drug on personhood  
 Results and outcomes of trial  
o Access to results post trial  
o Indirect positive results  
o Issues with outcome measurements  
o Negative effects 
o No direct results on FXS symptoms  
o Positive direct results on FXS symptoms  
o Terminated trial  
 Trial decision  
o Current decider  
o Decliner 
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